1. Madigan D, Shin J. Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. Open Access J Contracept. 2018;9:29-32.
2. PIONAS. Kontrasepsi hormonal kombinasi. 2020. https://pionas.pom.go.id/ioni/bab-7-obstetrik-ginekologik-dan-saluran-kemih/73-kontrasepsi/731-kontrasepsi-hormonal-kombinasi
3. Medscape. Drospirenone/ethinyl estradiol (Rx). 2020. https://reference.medscape.com/drug/yasmin-yaz-drospirenone-ethinyl-estradiol-342768
4. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344-54.
5. Fait T, Buryak D, Cirstoiu MM, Luczai E, Janczura R. Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs Context. 2018;7:212510. Published 2018 Feb 7. doi:10.7573/dic.212510.
6. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47):83334-83342. Published 2017 Aug 3. doi:10.18632/oncotarget.19833.
7. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane. Database of Systematic Reviews 2012, Issue 2. Art. No.: CD006586. DOI: 10.1002/14651858.CD006586.pub4.
8. Lucky AW, Koltun W, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008 Aug;82(2):143-50. PMID: 18792547.
9. Dinger J, Möhner S, Heinemann K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 75, 2007. 344 – 354. 20
10. Stewart, M. and Black, K., 2015. Choosing a combined oral contraceptive pill. Australian Prescriber, 38(1), pp.6-11.
11. Momoeda M, Akiyama S, Tanaka K, Suzukamo Y. Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study. Int J Womens Health. 2020;Volume 12:327-338. doi:10.2147/ijwh.s238460
12. Li L, Zhang R, Zeng J, et al. Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study. BMC Womens Health. 2020;20(1). doi:10.1186/s12905-020-00905-x
13. Foidart JM. Added benefits of drospirenone for compliance. Climacteric. 2005 Oct;8 Suppl 3:28-34. doi: 10.1080/13697130500330309. PMID: 16203653.
14. US Food and Drugs Administration. YAZ (drospirenone/ethinyl estradiol) tablets, for oral use. Accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021676s012lbl.pdf. Published 2012.
15. US Food and Drugs Administration. YASMIN (drospirenone/ethinyl estradiol) tablets, for oral use. Accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf. Published 2012.
16. Machado R, Pompei L, Giribela A, Giribela C. Drospirenone/Ethinylestradiol: A Review on Efficacy and Noncontraceptive Benefits. Women's Health. 2011;7(1):19-30. doi:10.2217/whe.10.84
17. Bayer Inc. Product Monograph, PrYASMIN® 21, PrYASMIN® 28. Drospirenone and Ethinyl Estradiol Tablets, Bayer Standard 3.0 mg drospirenone and 0.030 mg ethinyl estradiol. Oral Contraceptive. https://www.bayer.com/. https://www.bayer.com/sites/default/files/2020-11/yasmin-pm-en.pdf. Published 2022.
18. Bayer Inc. Yaz. Tablet Salut Selaput. Drospirenone 3 mg+Ethinylestradiol 0.02 mg. Bayer Inc, 2021.